)
John Grundy
Chief Development Officer and Co-founder,
Impilo Therapeutics
Dr. Grundy received his PhD from the University of Alberta and has more than 27 years of experience working in the pharmaceutical industry, including at Ionis Pharmaceuticals, Regulus Therapeutics, Neurocrine Biosciences, and Arena Pharmaceuticals. He has worked on multiple approved drugs , such as Kynamro® , Spinraza®, and Velsipity®, and has successfully progressed numerous small molecule, biologic, and oligonucleotide assets from early nonclinical testing thru to late-stage clinical development. He also previously co-founded and served on the board of directors of DTx Pharma, a preclinical stage biotechnology company addressing the delivery challenges of oligonucleotide therapeutics using its novel fatty acid ligand conjugate platform and that is now a subsidiary of Novartis.